SeaStar jumps on FDA's 'breakthrough' tag for liver disease treatment device

SeaStar Medical Holding

18/10/2023 15:30

** Shares of medtech company SeaStar Medical Holding  ICU.O 
rise ~50% to 68 cents
    ** Company says U.S. FDA has granted "breakthrough device"
designation for its device treating Hepatorenal syndrome (HRS)
    ** Breakthrough device designation helps patients gain
access to medical devices that may provide effective treatment
for which no approved or cleared alternatives exist
    ** HRS is a form of impaired kidney function that occurs in
people with advanced liver disease
    ** Including session's move, shares down ~83.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))